News

News
Share this article
08 May 2018

Successful Stakeholder Meeting boosts energy for future collaborative drug discovery

On 16 and 17 April 2018 the European Lead Factory (ELF) Target Owner Workshop and Stakeholder Meeting took place in the heart of Europe, Brussels. An exciting row of speakers allowed for a retrospect on five years of successfully seeding and nursing innovative drug discovery projects. It also gave a hint about the future and how we can further grow the successful ELF platform to serve drug discovery for priority medicines.

Read more
News
Share this article
24 April 2018

Prof Adam Nelson wins UCB-Ehrlich Award for Excellence in Medicinal Chemistry

On April 19, Prof Adam Nelson, University of Leeds, won the UCB-Ehrlich Award for Excellence in Medicinal Chemistry. This award was established to acknowledge and recognise outstanding research in the field of Medicinal Chemistry, and is the most prestigious prize an academic medicinal chemist can get.

Read more
News
Share this article
13 April 2018

The future of the European Lead Factory – preparing the next phase

As a public-private partnership, the European Lead Factory (ELF) has already been instrumental in boosting early drug discovery. Its continuing goal is to offer unrivalled opportunities for the discovery of new lead drug lead molecules – to public and private organisations – in order to address unmet medical needs.

Read more
Press Release
Share this article
03 April 2018

Servier and Scandicure enter into agreement to conduct research in the field of metabolic diseases

Paris and Gothenburg, 3 April 2018 – Servier, an independent international pharmaceutical company, and Scandicure, a Swedish spin-out of the University of Gothenburg, today announced the establishment of an agreement to exploit Scandicure’s innovation in the field of metabolic disease.

Read more
News
Share this article
29 March 2018

Memorandum of Understanding between REDEFAR and ELF strengthens European connections

Prof Mabel Loza, coordinator of REDEFAR, the Spanish Network of Excellence in Drug Discovery, and the European Lead Factory executives Dr Dimitrios Tzalis and Dr Ton Rijnders have signed a Memorandum of Understanding for collaboration in future initiatives.

Read more
News
Share this article
29 March 2018

Chemistry partner EDELRIS praises collaboration within ELF

EDELRIS, a medicinal chemistry company, shares several LinkedIn posts explaining the key factors in the European Lead Factory that make their work possible. In their second post, EDELRIS tells more about their collaboration with the academic groups: 

Read more
News
Share this article
20 March 2018

Extraordinary hit compounds with API-like properties

At the end of 2017, Prof Reuven Stein received an extraordinary Qualified Hit List from the European Lead Factory. His research group studies the tumour microenvironment (TME) and has discovered a protein that plays an essential role in tumour progression. With the promising ELF compounds, they hope to develop new treatments for cancers such as glioma and melanoma.

Read more
News
Share this article
14 March 2018

ELF collaboration brings French biotech CELLIPSE one step closer to cancer treatment

After receiving its Qualified Hit List last year, the biotech company CELLIPSE has been successfully working together with the European Lead Factory (ELF) on their Improved Hit List.

Read more
News
Share this article
02 March 2018

Pharma Focus Asia interviews Ton Rijnders about results and successes of ELF

In their latest newsletter, Pharma Focus Asia incorporated an interview with Ton Rijnders, Head of Screening at the European Lead Factory. They were curious about the results of the European Lead Factory, but also about the success factors, learnings and the future of ELF. 

Read more
News
Share this article
27 February 2018

European Commission: ‘ELF is leading the way to discovering new medicines’

Under the topic “Success Stories”, the European Commission recognises the impact and potential of the European Lead Factory. The Directorate-General Research and Innovation highlighted that ‘researchers working on any human disease can call on a great resource to develop new drugs.’ 

Read more

Pages